Frazier Life Sciences IX, L.P. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Oct 20, 2020
Insider Transaction Report
Form 4
Frazier Life Sciences IX, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2020-10-20$16.00/sh+312,500$5,000,000→ 1,917,157 total - Conversion
Common Stock
2020-10-20+214,281→ 1,604,657 total - Conversion
Series B Preferred Stock
2020-10-20−1,390,376→ 0 total→ Common Stock (1,390,376 underlying) - Conversion
Series C Preferred Stock
2020-10-20−214,281→ 0 total→ Common Stock (214,281 underlying) - Conversion
Common Stock
2020-10-20+1,390,376→ 1,390,376 total
Footnotes (2)
- [F1]Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
- [F2]The shares are held directly by Frazier Life Sciences IX, L.P. ("FLS LP"). The general partner of FLS LP is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, LLC. James Topper and Patrick Heron are the sole managing members of FHMLS IX, LLC, and share voting and dispositive power over the shares held by FLS LP. Each of Dr. Topper, Mr. Heron, FHMLS IX, L.P. and FHMLS IX, LLC disclaim beneficial ownership of the shares held by FLS LP, except to the extent of their pecuniary interest therein.